Drugs / [F-18]PBR06
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04144257 | Mar 2020 → Apr 2021 | multiple sclerosis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02649985 | May 2016 → Dec 2027 expected | Alzheimer disease, multiple sclerosis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT04616456 Background | Dec 2020 → Jan 2022 | multiple system atrophy, cerebellar type, multiple system atrophy, parkinsonian type | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03983252 Background | Dec 2021 → May 2024 | multiple sclerosis | Brigham and Women's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]PBR06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02649985 ↗ |
| Modality | Diagnostic / imaging agent | “PET radiopharmaceutical” NCT02649985 ↗ |
| Route | Intravenous | “an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer” NCT03983252 ↗ |